New Haven biopharma Trevi Therapeutics is planning to go public in hopes of raising $86 million to pay for late-stage clinical trials of its drug for severe chronic itching.
Trevi said it will use the money to further develop treatments for chronic pruritus (itching), chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia (a treatment-induced movement disorder) in patients with Parkinson’s disease.